Latest news with #life science
Globe and Mail
2 days ago
- Business
- Globe and Mail
Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company. Mehta brings extensive leadership and commercial expertise in biopharmaceutical, life science research, and diagnostics markets to Bio-Rad. He joins from Labcorp, where he served as Senior Vice President, overseeing large-scale commercial operations for the company's West Division. Prior to Labcorp, Mehta was Vice President and General Manager, Applied Technologies, at Thermo Fisher Scientific. In this role, he successfully managed a global business unit serving diverse markets. Earlier in his career, Mehta held commercial roles of increasing responsibility at Dow Chemical, where he designed and executed impactful commercial growth strategies. He holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Electrical Engineering from Kurkshetra University in Thanesar, India. "Rajat's proven track record in delivering above-market growth, building high-achieving teams, and driving alignment across multiple business segments will be instrumental as we continue to advance our long-term strategy,' said Jon DiVincenzo, Bio-Rad's President and Chief Operating Officer. 'His focus on commercial excellence and deep understanding of large, global organizations spanning both clinical diagnostics and life science markets make him a fantastic addition to our leadership team." Norman Schwartz, Bio-Rad's Chairman and CEO, added, "On behalf of everyone at Bio-Rad, I want to extend our deepest gratitude and acknowledgement to Mike Crowley for his exceptional service and unwavering dedication. Since joining our commercial team in 1998, and particularly during his tenure as EVP of Global Commercial Operations since 2014, Mike's leadership has been instrumental in building our global sales and services organization and contributing to Bio-Rad's overall success.' About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit Forward-Looking Statements This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our executive officers. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations; global economic and geopolitical conditions; tariffs or other trade barriers; reductions in government funding or capital spending of our customers; the uncertain pace of the biopharma sector's recovery; international legal and regulatory risks; our ability to develop and market new or improved products; our ability to compete effectively; foreign currency exchange fluctuations; supply chain issues; product quality and liability issues; our ability to integrate acquired companies, products or technologies into our company successfully; changes in the healthcare industry; and natural disasters and other catastrophic events beyond our control. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Associated Press
21-07-2025
- Business
- Associated Press
Biocom California and Los Angeles County Economic Development Corporation Renew Memorandum of Understanding to Advance the Greater Los Angeles Life Science Ecosystem
LOS ANGELES & SAN DIEGO & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul 21, 2025-- Biocom California, the association representing the California life science industry, and the Los Angeles County Economic Development Corporation (LAEDC), a leader in inclusive economic growth, today announced the renewal of a Memorandum of Understanding (MOU) aimed at strengthening the life science ecosystem in the Greater Los Angeles region. 'Greater Los Angeles is home to a thriving life science cluster, powered by world-class research institutions and a diverse, innovation-driven economy,' said Dan Gober, Executive Director, Los Angeles of Biocom California. 'This renewed partnership with LAEDC enables us to double down on the commitment we made when we first opened our Greater LA office in 2015 to address the unique needs of the LA life science community, connect it with complementary regional hubs across Southern California, and ensure that groundbreaking discoveries made here stay and scale here.' Under the MOU, Biocom California and LAEDC will collaborate on strategic programs and initiatives to support growth and innovation in Los Angeles County's bioscience sector. Key objectives include aligning resources and networks to: Los Angeles County is a critical player in the global bioeconomy, bolstered by internationally renowned institutions such as UCLA, USC, Cedars-Sinai Medical Center, Caltech and City of Hope. The region is home to more than 3,966 life science establishments, providing close to 200,000 jobs and generating over $60 billion in economic output. In 2024 alone, the region secured $1.51 billion in federal funding from the NIH and NSF, underscoring its prominence as a center of scientific advancement. 'LAEDC's partnership with Biocom California reflects our shared vision for inclusive and sustainable economic growth driven by innovation,' said Stephen Cheung, president and CEO of LAEDC. 'The life sciences are essential to that vision: delivering transformative health outcomes, creating quality jobs, and strengthening our position in global markets. Together, we will continue to support and elevate this high-impact industry throughout Los Angeles County.' The MOU also outlines collaboration on signature events, joint policy and workforce initiatives, and the implementation of the LA County Bioscience Strategic Plan. Both organizations will engage public and private stakeholders, leveraging their unique assets to accelerate the life sciences sector's impact on local communities and the broader economy. About Biocom California Biocom California is the leader and advocate for California's life science sector. We work on behalf of our members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs and create robust value-driven purchasing programs. Founded in 1995 in San Diego, Biocom California provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to our San Diego headquarters, Biocom California operates core offices in Los Angeles and the San Francisco Bay Area, with satellite offices in Sacramento, Washington, D.C. and Tokyo. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers. For more information on Biocom California, please visit our website at Connect with us on LinkedIn, Facebook and X. View source version on CONTACT: Biocom California Media Contact: Carolyn Hawley Inizio Evoke Comms (619) 849-5382 [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES GENETICS OTHER SCIENCE SCIENCE PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Biocom California Copyright Business Wire 2025. PUB: 07/21/2025 02:18 PM/DISC: 07/21/2025 02:18 PM
Yahoo
16-07-2025
- Business
- Yahoo
Alexandria Secures Lease at Its Megacampus in San Diego
Alexandria Real Estate Equities, Inc. ARE secured the largest life science lease in its 31 years of history by signing a 16-year lease agreement with a longtime multi-national pharmaceutical tenant. The lease for this build-to-suit research hub spans over 466,598 rentable square feet (RSF) of space located at Campus Point by Alexandria Megacampus in the University Town Center submarket of San Diego. This lease highlights the demand for Alexandria's premier location for life science innovation in San Diego. The construction of this development project, aimed at achieving 100% electrification along with LEED Gold Core & Shell and Fitwel certifications, is set to begin in 2026, with an expected completion in 2028. This high-performance laboratory facility emphasizes energy efficiency and minimizes water consumption, alongside focusing on the health and wellness of its occupants. Its distinctive design incorporates natural light, optimizes shared spaces to encourage connectivity and includes a spacious terrace that functions as a central gathering area, seamlessly integrating indoor and outdoor spaces. In 1994, Alexandria took the lead in life science real estate with its founding and first acquisition in San Diego. Since the acquisition of its first Campus Point property in 2010, the company has been carefully aggregating, designing, entitling, developing and transforming assets to create an irreplicable Megacampus ecosystem featuring a solid and diverse tenant base, which drives high-quality long-term cash flows. As of June 30, 2025, Campus Point comprises 1.3 million RSF in operation and is 98.8% occupied. With nearly 1.3 million RSF of additional future development and redevelopment opportunities, this Megacampus could potentially expand to about 2.6 million RSF, reflecting 420% growth in its scale from the initial acquisition. The campus is well-positioned to provide tenants with crucial expansion space and an enhanced amenity experience, which aids in recruiting and retaining mission-critical talent to foster next-generation innovations. Alexandria is the preeminent, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. Alexandria caters to a diversified tenant base comprising high-quality companies ranging from multinational pharmaceutical companies, public and private biotechnology companies, manufacturers of complex medicines and top-tier investment-grade companies and institutions as well as technology entities. However, with a substantial concentration of companies belonging to the life science and technology industries, Alexandria's performance remains susceptible to any changes within these industries. The company's substantial active development and redevelopment pipeline, although encouraging for long-term growth, exposes it to the risk of rising construction costs and lease-up concerns amid macroeconomic uncertainty. In the past three months, shares of this Zacks Rank #5 (Sell) company have gained 2% compared with the industry's rise of 5.3%. Image Source: Zacks Investment Research Some better-ranked stocks from the broader REIT sector include SBA Communications SBAC and American Tower AMT, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for SBAC's 2025 FFO per share has moved 3 cents northward to $12.74 over the past two months. The Zacks Consensus Estimate for AMT's 2025 FFO per share has moved 2 cents northward to $10.55 over the past week. Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report American Tower Corporation (AMT) : Free Stock Analysis Report SBA Communications Corporation (SBAC) : Free Stock Analysis Report Alexandria Real Estate Equities, Inc. (ARE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-07-2025
- Business
- Yahoo
Scotiabank Upgrades Thermo Fisher (TMO) to Outperform, Lowers PT
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 11, Scotiabank upgraded its rating for Thermo Fisher Scientific Inc. (NYSE:TMO) from 'Sector Perform' to 'Outperform' while also setting a new price target of $590, down from the previous $605. The bank believes that the stock has been 'disproportionately impacted' because of healthcare and trade policy talks and changes this year. A workstation in a research lab stocked with laboratory products and services. Scotiabank expects Thermo Fisher Scientific Inc. (NYSE:TMO) to grow faster once the concerns about US healthcare policy changes go away. This growth is expected to be driven by the company's 'unparalleled commercial scale' and improved region-for-region capabilities anticipated by 2026. The firm also pointed out that Thermo Fisher Scientific Inc.'s (NYSE:TMO) leading position in innovation, operational execution, and cash flow potential as key strengths that position the company well in the life science tools industry. In this industry, Thermo Fisher Scientific Inc. (NYSE:TMO) is the largest company 'by a significant margin.' Thermo Fisher Scientific Inc. (NYSE:TMO) is a leading life science and clinical research company that supplies analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical, and biotechnology services. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-07-2025
- Business
- Yahoo
Scotiabank Upgrades Thermo Fisher (TMO) to Outperform, Lowers PT
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 11, Scotiabank upgraded its rating for Thermo Fisher Scientific Inc. (NYSE:TMO) from 'Sector Perform' to 'Outperform' while also setting a new price target of $590, down from the previous $605. The bank believes that the stock has been 'disproportionately impacted' because of healthcare and trade policy talks and changes this year. A workstation in a research lab stocked with laboratory products and services. Scotiabank expects Thermo Fisher Scientific Inc. (NYSE:TMO) to grow faster once the concerns about US healthcare policy changes go away. This growth is expected to be driven by the company's 'unparalleled commercial scale' and improved region-for-region capabilities anticipated by 2026. The firm also pointed out that Thermo Fisher Scientific Inc.'s (NYSE:TMO) leading position in innovation, operational execution, and cash flow potential as key strengths that position the company well in the life science tools industry. In this industry, Thermo Fisher Scientific Inc. (NYSE:TMO) is the largest company 'by a significant margin.' Thermo Fisher Scientific Inc. (NYSE:TMO) is a leading life science and clinical research company that supplies analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical, and biotechnology services. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
